Vico Therapeutics
PrivateLast Round
Series B
Extension
Jun 24, 2024
Total Funding Raised
$114.1M
Company Overview
Vico Therapeutics operates in Healthcare & Life Sciences and is based in Leiden. Its latest recorded funding round was a Series B Extension round in June 2024.
Vico Therapeutics is a biotechnology company that develops RNA-modulating antisense oligonucleotide (ASO) therapies aimed at treating patients with severe, rare neurological disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Vico Therapeutics Comparables
Compare Vico Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Arexera Therapeutics | 83% | |
| Wave Life Sciences | 81% | |
| ProQR Therapeutics | 79% |
For institutional investors. Book with your work email.
Vico Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Jun 24, 2024 | ||||
| Series B | Jan 5, 2024 | ||||
| Series A | Jul 29, 2020 |
For institutional investors. Book with your work email.
Vico Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Ackermans & van Haaren | Series B Extension, Series B |
| EQT Life Sciences | Series B Extension, Series A, Series B |
| Idinvest Partners | Series A |
| Seroba Life Sciences | Series B Extension |
| Pontifax Credit | Series A |
| Droia Ventures | Series B Extension, Series A, Series B |
| Pureos Bioventures | Series A, Series B, Series B Extension |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 1, 2025
Product candidate VO659 is undergoing a first-in-human study for rare neurological disorders.
- Jun 22, 2025
Job posting indicates preparation for IPO as part of growth strategy.
For institutional investors. Book with your work email.
Vico Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Vico Therapeutics's valuation, stock price, and market status.
Is Vico Therapeutics a public or private company?
Vico Therapeutics is a private company.
What is the current stock price of Vico Therapeutics?
Vico Therapeutics is a private company, so its shares have no public market price. Caplight tracks Vico Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Vico Therapeutics worth (valuation)?
Valuation information for Vico Therapeutics is not publicly available.
Can I buy Vico Therapeutics stock?
Vico Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Vico Therapeutics's last funding round?
Vico Therapeutics's most recent funding round was Series B Extension on June 24, 2024.
Who are the main investors in Vico Therapeutics?
Key investors in Vico Therapeutics include Ackermans & van Haaren, EQT Life Sciences, Eurazeo, Kurma Partners.
Will Vico Therapeutics IPO soon?
No public IPO plans have been announced for Vico Therapeutics.
How can I track Vico Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Vico Therapeutics's shares on secondary markets.